Universal Beteiligungs und Servicegesellschaft mbH Raises Stake in GeneDx Holdings Corp. $WGS

Universal Beteiligungs und Servicegesellschaft mbH grew its holdings in shares of GeneDx Holdings Corp. (NASDAQ:WGS) by 95.0% during the 3rd quarter, HoldingsChannel reports. The fund owned 36,811 shares of the company’s stock after acquiring an additional 17,936 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in GeneDx were worth $3,966,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC bought a new position in shares of GeneDx during the 3rd quarter valued at $673,000. Sumitomo Mitsui Trust Group Inc. purchased a new stake in GeneDx during the third quarter valued at about $31,488,000. State of Alaska Department of Revenue bought a new position in shares of GeneDx during the third quarter valued at about $187,000. Nisa Investment Advisors LLC increased its holdings in shares of GeneDx by 1,718.1% in the third quarter. Nisa Investment Advisors LLC now owns 3,618 shares of the company’s stock worth $390,000 after buying an additional 3,419 shares during the period. Finally, Benjamin Edwards Inc. purchased a new position in shares of GeneDx in the third quarter worth about $480,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

GeneDx Trading Down 8.3%

NASDAQ:WGS opened at $96.22 on Wednesday. The company has a 50-day moving average price of $136.21 and a 200-day moving average price of $124.56. The stock has a market cap of $2.78 billion, a price-to-earnings ratio of 1,069.09 and a beta of 2.01. The company has a current ratio of 2.71, a quick ratio of 2.59 and a debt-to-equity ratio of 0.18. GeneDx Holdings Corp. has a 12 month low of $55.17 and a 12 month high of $170.87.

GeneDx (NASDAQ:WGS) last released its quarterly earnings results on Tuesday, October 28th. The company reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.21. The company had revenue of $116.74 million during the quarter, compared to the consensus estimate of $104.33 million. GeneDx had a net margin of 0.52% and a return on equity of 20.22%. Equities analysts predict that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Wall Street Analysts Forecast Growth

WGS has been the topic of several recent research reports. Zacks Research lowered GeneDx from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 2nd. Wells Fargo & Company set a $155.00 price objective on GeneDx and gave the company an “equal weight” rating in a research note on Monday, December 15th. Wall Street Zen downgraded shares of GeneDx from a “buy” rating to a “hold” rating in a research note on Saturday, November 1st. Guggenheim reiterated a “buy” rating and set a $170.00 price target (up from $115.00) on shares of GeneDx in a report on Wednesday, October 29th. Finally, Canaccord Genuity Group raised their price target on shares of GeneDx from $160.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, December 22nd. Six analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $138.13.

Insiders Place Their Bets

In related news, CFO Kevin Feeley sold 3,855 shares of the company’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $143.87, for a total value of $554,618.85. Following the sale, the chief financial officer directly owned 8,731 shares of the company’s stock, valued at $1,256,128.97. This represents a 30.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Joshua Ruch sold 38,000 shares of the firm’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $160.37, for a total value of $6,094,060.00. Following the transaction, the director directly owned 11,941 shares of the company’s stock, valued at $1,914,978.17. This represents a 76.09% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 57,617 shares of company stock worth $8,992,161. Company insiders own 29.60% of the company’s stock.

GeneDx Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.